# IGC Pharma, Inc.: Form 10-KT, filed Mar 18, 2026

- Company: [IGC Pharma, Inc.](/companies/igc.md) (CIK 1326205)
- Form: 10-KT
- Filed: 2026-03-18
- Accepted by EDGAR: Mar 18, 2026, 16:02 ET
- Period: 2025-12-31
- Accession: 0001185185-26-000941
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1326205/000118518526000941/igc10kt123125.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1326205/000118518526000941/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2025-12-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 9 months, 2025-04-01 to 2025-12-31 | $869.0k | us-gaap:Revenues |
| Cost of revenue | 9 months, 2025-04-01 to 2025-12-31 | $572.0k | us-gaap:CostOfRevenue |
| Gross profit | 9 months, 2025-04-01 to 2025-12-31 | $297.0k | us-gaap:GrossProfit |
| Research and development | 9 months, 2025-04-01 to 2025-12-31 | $3.9m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 9 months, 2025-04-01 to 2025-12-31 | $4.1m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 9 months, 2025-04-01 to 2025-12-31 | −$7.7m | us-gaap:OperatingIncomeLoss |
| Income tax | 9 months, 2025-04-01 to 2025-12-31 | $0 | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 9 months, 2025-04-01 to 2025-12-31 | −$4.1m | us-gaap:NetIncomeLoss |
| Diluted EPS | 9 months, 2025-04-01 to 2025-12-31 | −$0.05 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 9 months, 2025-04-01 to 2025-12-31 | −$0.05 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 9 months, 2025-04-01 to 2025-12-31 | 88,851,556 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months, 2025-04-01 to 2025-12-31 | −$4.7m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months, 2025-04-01 to 2025-12-31 | $49.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2025-12-31 | $900.0k | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2025-12-31 | $1.8m | us-gaap:AssetsCurrent |
| Total assets | at 2025-12-31 | $9.7m | us-gaap:Assets |
| Current liabilities | at 2025-12-31 | $2.2m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2025-12-31 | $2.3m | us-gaap:Liabilities |
| Long-term debt | at 2025-12-31 | $131.0k | us-gaap:LongTermDebtNoncurrent |
| Short-term borrowings | at 2025-12-31 | $3.0k | us-gaap:ShortTermBorrowings |
| Shareholders' equity | at 2025-12-31 | $7.4m | us-gaap:StockholdersEquity |

## Sections

Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. https://www.sec.gov/Archives/edgar/data/1326205/000118518526000941/igc10kt123125.htm

Filed Mar 18, 2026.
Source: SEC EDGAR, the filing index for accession 0001185185-26-000941. Last ingested by Listed: Nov 6, 2026, 16:27 ET. No prices; not investment advice.
